Delivery Order W911SR24D0001-W911SR26FA005
Award Date 1/4/26
Potential Completion Date 9/30/29
Potential Value $67M
Funding Federal Agency
Contracting Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Available for Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Lansing, MI 48906, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $41,801,810.00 firm fixed-price delivery order contract to Emergent Biodefense Operations Lansing LLC, doing business as Emergent Biodefense, for the procurement of BioThrax (Anthrax Vaccine Adsorbed). This contract, which is not a set-aside, has an ultimate completion date of September 30, 2025. Emergent Biodefense is the prime contractor and manufacturer of BioThrax, the only...
- This is a definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Biodefense Operations Lansing LLC, a for-profit manufacturer of medical countermeasures. The $1,174,464,339.10 firm fixed-price contract is for the production of BioThrax, the only FDA-licensed vaccine for the prevention of anthrax disease, which is a critical component of the U.S. government's strategic national stockpile. The...
- This is a $43,794,113.43 cost-plus-fixed-fee definitive contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit manufacturer, for the advanced development of NuThrax (Anthrax Vaccine Absorbed with CPG 7909) or AV7909. The contract has an ultimate completion date of July 31, 2019 and was awarded on March 23, 2015. There is no set-aside designation for this...
- The U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded Emergent Product Development Gaithersburg Inc. a firm fixed price contract valued at $804.9 million on August 30, 2019, for the manufacture and delivery of ACAM2000, a live vaccinia smallpox vaccine. The contract, which extends through August 29, 2029, supports the federal government's medical countermeasures stockpiling and pandemic preparedness initiatives. Work will be...
- This delivery order, awarded on January 6, 2026, procures ENGERIX-B 20 micrograms per milliliter vaccine syringes valued at $1,533.22 for the Defense Logistics Agency (DLA). The award was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, with performance taking place at the same location. The contract was competitively awarded with no set-aside designation and utilizes firm fixed-price pricing, with an ultimate completion...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution and supply company. The contract is a Delivery Order with a Firm Fixed Price of $1,243.99, for the supply of the vaccine product ENGERIX-B 20 MCG/ML VIALML. The contract has a completion date of April 30, 2024 and was awarded on April 29, 2024. This contract is not set aside for any specific business category. Amerisourcebergen Drug Corp, through its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of ENGERIX-B 20 MCG/ML vaccine at a ceiling value of $1,435.25. This is a firm fixed price delivery order with no set-aside designation, reflecting competitive procurement practices. The work is performed at AmerisourceBergen's Conshohocken, Pennsylvania location, with an ultimate completion date of September 11, 2025. This delivery order is executed under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,555.46 to Amerisourcebergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine, with a completion date of January 8, 2026. This is a firm fixed-price, non-set-aside contract executed on January 7, 2026, with performance to be completed at the contractor's facility in Conshohocken, Pennsylvania. Amerisourcebergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is a subsidiary of parent...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of ENGERIX-B PEDI 10 MCG/0.5 ML syringes, a pediatric hepatitis B vaccine. This non-set-aside, firm fixed-price delivery order has a ceiling value of $1,373.50 and an ultimate completion date of October 30, 2025. The contract is performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major...
- The Defense Logistics Agency awarded a $2,125.04 delivery order to AmerisourceBergen Drug Corp for Trumenba 120 MCG/0.5 ML vaccine on September 19, 2025, with an ultimate completion date of September 22, 2025. This competitively awarded, firm fixed-price contract is classified as a delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...